Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Mirvetuximab · Elahere, M-9346A

Antibody-drug conjugate · Cytotoxic, directed at folate receptor alpha (FOLR1) · developed by Immunogen

Approved FDA
1 Registered trials

What is Mirvetuximab?

Mirvetuximab soravtansine-gynx is an antibody-drug conjugate in which a chimeric IgG1 antibody binds folate receptor alpha, and a microtubule inhibitor, DM4, is attached by a cleavable linker. After internalization, DM4 is released inside the cell, disrupting the microtubule network, causing cell cycle arrest and apoptotic death. It is studied in ovarian, fallopian tube and primary peritoneal cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Elahere, M-9346A
Drug type
Antibody-drug conjugate
Targets
folate receptor alpha (FOLR1)
Mechanism
Cytotoxic, directed at folate receptor alpha (FOLR1)
Pathways
microtubule disruption, cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
Immunogen, Inc.
In trials of
STTK
FDA status
Approved as Elahere, BLA761310 · FDA label
UNII
4MFH3B1EFU

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 14, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05483933 Phase 1 Platinum-resistant Ovarian Cancer Completed STTK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Epithelial Ovarian CancerFallopian Tube CancerOvarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-resistant Ovarian CancerPlatinum-Resistant Primary Peritoneal CarcinomaPrimary Peritoneal Carcinoma

Other drugs acting on FOLR1

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.